Table 1.

Trial and patient characteristics

	Recruitment			Eligibility criteria				Treatment
	Date of first randomization	Total randomized	Stage II randomized	Tumor site	Age limit (years)	Tumor stage	Start therapy after surgery (days)	Comparator	Treatment	Number of cycles	Duration (months)	Median follow‐up (years)
IMPACT (1999)
GIVIO	January 1989	888	449	Colon	None	II and III1	35	Control	FU + LV	6	6	5.3
NCIC‐CTG	May 1987	370	221	Colon	None	II and III1	56	Control	FU + LV	6	6	5.9
FFCD	October 1982	268	168	Colon	<75	II and III1	35	Control	FU + LV	6	6	5.2
NNCTG	February 1988	317	57	Colon	None	II and III1	35	Control	FU + LV	6	6	6.4
Sienna	January 1985	239	121	Colon	None	II and III1	21	Control	FU + LV	12	12	8.5
QUASAR (2007)	May 1994	3,239	2,963	Colon/Rectum	None	I, II and III	42	Control	FU + LV	6	6	5.5
Schippinger et al. (2007)	November 1993	500	500	Colon	<80	II	42	Control	5‐FU + LV	7	13	8.0
MOSAIC (2009)	October 1998	2,246	899	Colon	<75	II, III	42	LV5FU2	FOLFOX4	12	6	6.8
NSABP C07 (2011)	February 2000	2,492	695	Colon	None	II,III	NR	FULV	FLOX	3	6	8.0

¹ Dukes classification was used in these studies. Stage II: Dukes B2, tumor has grown through the gut, but not yet in lymph nodes. Stage III: Dukes C, tumor has grown into the regional lymph nodes.

Abbreviations: FOLFOX, regimen that includes the drugs leucovorin, fluoropyrimidine and oxaliplatin; FU, fluoropyrimidine; LV, leucovorin; NA, not applicable; NR, not reported.